Comparing Subsidized Access to Medicines Across Payer Systems
- 270 Downloads
We note the original research article by Ragupathy et al.  from New Zealand (NZ) on access to licensed and subsidized medicines under single-payer systems in the USA, the UK, Australia and NZ published in the November 2012 issue of PharmacoEconomics. This cross-sectional study found that the UK NHS subsidized the most entities, the newest entities and the most innovative entities; and that NZ’s Pharmaceutical Management Agency (PHARMAC) subsidized the fewest entities, the oldest entities and the fewest innovative entities . Similarly, we reported 12 months earlier that in the past decade, public access to new medicines in NZ was more limited and delayed compared with Australia, which we attributed largely to a capped pharmaceuticals budget . Unfortunately, these authors did not cite our paper.
We understand the authors’ motivation to include the USA as a study country. The challenge is to find a representative payer system, as the USA has many payers and no true...
KeywordsRabies Pharmaceutical Benefit Scheme Pharmaceutical Benefit Advisory Committee Australian Pharmaceutical Benefit Scheme Medicine Price Review
No funding was received for this letter and no other individual or organization was involved. The authors have no conflicts of interest.
- 7.Department of Health and Ageing. National immunisation program schedule. Canberra: Australian Government; 2012. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips2. Accessed 19 Oct 2012.
- 8.New Zealand Ministry of Health. National immunisation register. Wellington: New Zealand Government; 2012. http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/national-immunisation-register. Accessed 20 Oct 2012.